Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial.

Ahmed AI, van den Elsen GA, Colbers A, van der Marck MA, Burger DM, Feuth TB, Rikkert MG, Kramers C.

Eur Neuropsychopharmacol. 2014 Sep;24(9):1475-82. doi: 10.1016/j.euroneuro.2014.06.007.

PMID:
25035121
2.

Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.

Klumpers LE, Beumer TL, van Hasselt JG, Lipplaa A, Karger LB, Kleinloog HD, Freijer JI, de Kam ML, van Gerven JM.

Br J Clin Pharmacol. 2012 Jul;74(1):42-53. doi: 10.1111/j.1365-2125.2012.04164.x.

3.

Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.

de Vries M, Van Rijckevorsel DC, Vissers KC, Wilder-Smith OH, Van Goor H.

Br J Clin Pharmacol. 2016 Mar;81(3):525-37. doi: 10.1111/bcp.12811.

4.
5.

Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia.

Ahmed AI, van den Elsen GA, Colbers A, Kramers C, Burger DM, van der Marck MA, Olde Rikkert MG.

Psychopharmacology (Berl). 2015 Jul;232(14):2587-95. doi: 10.1007/s00213-015-3889-y.

6.
7.
9.

Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations.

Huestis MA, Elsohly M, Nebro W, Barnes A, Gustafson RA, Smith ML.

Ther Drug Monit. 2006 Aug;28(4):540-4.

PMID:
16885722
10.
11.
12.

Effects of 20 mg oral Δ(9) -tetrahydrocannabinol on the olfactory function of healthy volunteers.

Walter C, Oertel BG, Ludyga D, Ultsch A, Hummel T, Lötsch J.

Br J Clin Pharmacol. 2014 Nov;78(5):961-9. doi: 10.1111/bcp.12415.

13.

A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.

Stott CG, White L, Wright S, Wilbraham D, Guy GW.

Eur J Clin Pharmacol. 2013 Apr;69(4):825-34. doi: 10.1007/s00228-012-1393-4.

PMID:
23052407
14.

Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.

Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA.

Clin Chem. 2011 Jan;57(1):66-75. doi: 10.1373/clinchem.2010.152439.

15.

Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.

Milman G, Bergamaschi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, Huestis MA.

Ther Drug Monit. 2014 Apr;36(2):218-24. doi: 10.1097/FTD.0b013e3182a5c446.

16.

Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy.

Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN.

J Pain. 2008 Mar;9(3):254-64.

PMID:
18088560
17.

Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial.

Hunault CC, Böcker KB, Stellato RK, Kenemans JL, de Vries I, Meulenbelt J.

Psychopharmacology (Berl). 2014 Dec;231(24):4723-33. doi: 10.1007/s00213-014-3630-2.

PMID:
24879495
18.

Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans.

D'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, Carbuto M, Elander J, Schnakenberg A, Pittman B, Sewell RA, Ranganathan M, Mathalon D.

Neuropsychopharmacology. 2012 Jun;37(7):1632-46. doi: 10.1038/npp.2012.8.

19.
20.

Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model.

Hunault CC, van Eijkeren JC, Mensinga TT, de Vries I, Leenders ME, Meulenbelt J.

Toxicol Appl Pharmacol. 2010 Aug 1;246(3):148-53. doi: 10.1016/j.taap.2010.04.019.

PMID:
20450927

Supplemental Content

Support Center